Artemis Q4 Revenue up 7%, EBITDA Rises 21%, Net Profit Jumps 60%

14 May 2025 CW Team

The Board of Directors of Artemis Medicare Services today approved the company’s audited financial results for the 4th quarter (Jan to Mar) and 12M (Apr to Mar) for the financial year 2024 – 25.

For the quarter ended March 31, 2025 Artemis Medicare Services, on a consolidated level, registered a gross revenue of Rs 2,521 Million, an increase of 7.0 per cent over the same period last fiscal. For the fiscal year (April – March), the company’s gross revenue closed at Rs 9,819 Million, an increase of 6.5 per cent over the same period last fiscal. The Board of Directors have recommended a final dividend of 45 per cent per Equity Share of face value of Re 1 each for FY25, subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM) of the Company.

Commenting on the company’s performance, Onkar Kanwar, Chairman, Artemis Medicare Services said “Artemis concluded FY25 on a strong and positive trajectory, delivering consistent performance and steady growth across the year. We have continued to advance in both clinical excellence and operational capabilities, reaffirming our commitment to provide high-quality, accessible healthcare to the communities we serve. During the year we also inaugurated our third tower, which will be commissioned in a phase-wise manner to accommodate the increasing demand from our growing patient base.

To fuel our next growth phase, we raised Rs 3.30 billion from the International Finance Corporation (IFC), enabling strategic expansion across Delhi NCR and select Tier 2 cities through both brownfield and greenfield projects. The Board has approved a long-term Operations & Management and Medical Services Agreement for a 300+ bed super-speciality hospital in Raipur. This deal marks a key step in expanding our footprint in Central India and reinforces our mission to deliver advanced healthcare solutions across geographies. As we look ahead, our unwavering focus remains on creating long-term value for our patients, shareholders, and employees, while building Artemis into one of India’s most trusted and respected healthcare brands.”

The Board of Directors of Artemis Medicare Services today approved the company’s audited financial results for the 4th quarter (Jan to Mar) and 12M (Apr to Mar) for the financial year 2024 – 25.For the quarter ended March 31, 2025 Artemis Medicare Services, on a consolidated level, registered a gross revenue of Rs 2,521 Million, an increase of 7.0 per cent over the same period last fiscal. For the fiscal year (April – March), the company’s gross revenue closed at Rs 9,819 Million, an increase of 6.5 per cent over the same period last fiscal. The Board of Directors have recommended a final dividend of 45 per cent per Equity Share of face value of Re 1 each for FY25, subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM) of the Company.Commenting on the company’s performance, Onkar Kanwar, Chairman, Artemis Medicare Services said “Artemis concluded FY25 on a strong and positive trajectory, delivering consistent performance and steady growth across the year. We have continued to advance in both clinical excellence and operational capabilities, reaffirming our commitment to provide high-quality, accessible healthcare to the communities we serve. During the year we also inaugurated our third tower, which will be commissioned in a phase-wise manner to accommodate the increasing demand from our growing patient base.To fuel our next growth phase, we raised Rs 3.30 billion from the International Finance Corporation (IFC), enabling strategic expansion across Delhi NCR and select Tier 2 cities through both brownfield and greenfield projects. The Board has approved a long-term Operations & Management and Medical Services Agreement for a 300+ bed super-speciality hospital in Raipur. This deal marks a key step in expanding our footprint in Central India and reinforces our mission to deliver advanced healthcare solutions across geographies. As we look ahead, our unwavering focus remains on creating long-term value for our patients, shareholders, and employees, while building Artemis into one of India’s most trusted and respected healthcare brands.”

Infrastructure Energy

22 Oct 2025

KEC Secures Rs 10, 380 Mn Substation Order in Saudi Arabia

KEC International Ltd., a global infrastructure EPC major, and an RPG Group company, has secured a new order worth Rs 10,380 million for the Design, Supply and Installation of a 380 kV GIS Substation in Saudi Arabia.Vimal Kejriwal, MD & CEO, KEC International Ltd., commented, “We are delighted with the successive order wins in our T&D business. In a landmark achievement, we have secured our largest ever substation order. This prestigious order in the Middle East has widened our portfolio and strengthened our presence in the region. With this strategic win, our year-to-date or..

Infrastructure Urban

22 Oct 2025

Central Bank of India executes first fully digital SCF deal on PSB Xchange

In a major advancement for India’s banking sector, Central Bank of India (CBI) has successfully completed the country’s first fully digital supply chain finance (SCF) transaction on PSB Xchange—a unified multi-lender platform launched by PSB Alliance. PSB Xchange is designed to connect public and private sector banks, NBFCs, and fintechs with corporates and their channel partners to facilitate supply chain finance and small business loans. The transaction marks the first time a fintech-originated corporate lead has been seamlessly processed through the PSB Xchange ecosystem. The lead fl..

Infrastructure Energy

22 Oct 2025

Atlanta Electricals secures Rs 1,835 Mn transformer order from BNC Power

Atlanta Electricals Limited (“Atlanta”) has secured an order worth Rs 1,835 million from BNC Power Projects Ltd for the supply of extra high voltage (EHV) transformers and a bus reactor for its Pugal site. The contract includes a mix of 315 MVA, 400 KV and 100 MVA, 132 KV transformers along with a 400 KV bus reactor. The project scope encompasses design, manufacturing, testing, and supply to the project site. Deliveries will be sequenced following engineering and drawing approvals, offering multi-quarter execution visibility and ensuring a steady production run-rate. The order will be ex..